EOM Pharmaceutical Holdings Inc. (IMUC)

[Investor100]

Pipeline @ IMUC

http://www.imuc.com/pipeline

ICT-107
ImmunoCellular has reached agreement with the US FDA on a Special Protocol Assessment (SPA) relative to the primary and secondary endpoints as well as the statistical plan for the phase 3 trial. ImmunoCellular has also been awarded $19.9 million from the governing Board of the California Institute for Regenerative Medicine (CIRM), California’s stem cell agency, for the phase 3 registration trial.

ICT-121
ICT-121 specifically targets CD133, a cancer stem cell marker that is overexpressed in a wide variety of solid tumors, including ovarian, pancreatic, and breast cancers.

Stem-to-T-Cell Program
n September 2014, ImmunoCellular entered into a licensing agreement with the California Institute of Technology (Caltech) for exclusive rights to novel technology for the development of stem cell immunotherapies for the treatment of cancer. The technology originated from the labs of David Baltimore, PhD, Nobel Laureate and President Emeritus at Caltech, and utilizes the patient’s own hematopoietic stem cells to create antigen-specific killer T cells to treat cancer. ImmunoCellular plans to utilize this technology to expand and complement its dendritic cell-based cancer immunotherapy platform, with the goal of developing new immunotherapies that kill cancer cells in a highly directed and specific manner and that can function as monotherapies or in combination therapy approaches.